Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience

Chimeric antigen receptor (CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma and results in a unique toxicity profile, namely cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome. The hyper-inflammatory state associated with these toxicities has been suggested to increase the risk of thrombosis.
We conducted a retrospective analysis of patients treated with axicabtagene ciloleucel (axi-cel) to assess the rate of thrombosis with axi-cel therapy from the time of CAR T-cell infusion until the end of hospitalization, when performed in the inpatient setting, or up to day +30 when performed in the outpatient setting. Ninety-two (95%) of 97 patients were hospitalized during axi-cel therapy and 85 (88%) developed CRS. Fifty-five patients (57%) received concurrent anticoagulation (53 as prophylaxis). Patients with prior VTE did not have progression https://joplink.net/antigens/ or evidence of new VTE. Only 2 (2.1%) patients developed VTE. These results demonstrate a low-risk for thrombosis in axi-cel recipients.

The Protective Action of Piperlongumine Against Mycobacterial Pulmonary Tuberculosis in Its Mitigation of Inflammation and Macrophage Infiltration in Male BALB/c Mice

Introduction: Piperlongumine (PL) is a bioactive alkaloid and medicinal compound of piperamide isolated from the long pepper (Piper longum Linn). It has demonstrated bactericidal action against Mycobacterium tuberculosis (MTB), the cause of pulmonary tuberculosis; nevertheless, immunomodulatory activity had not been identified for it in MTB-triggered granulomatous inflammation. This study investigated if piperlongumine could inhibit such inflammation.
Material and methods: Mycobacterium tuberculosis strain H37Rv was subjected to a broth microdilution assay. Piperlongumine at 5, 15, and 25 μg/mL, 0.2% dimethyl sulphoxide as control or 4 μM of dexamethasone were tested in vitro on MH-S murine alveolar macrophages. BALB/c mice were orally administered PL at 50, 100 and 150 mg/kg b.w. after trehalose-6,6-dimycolate (TDM) stimulation.
Chemokine and cytokine concentrations were determined in lung supernatants. Flow cytometry and Western blot analysis were performed to determine phosphorylated spleen tyrosine kinase (Syk), c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) pathways.
Results: Piperlongumine inhibited inflammatory mediators and adherence of lymphocyte function-associated antigen 1 to MH-S cells following TDM activation. It also improved macrophage clearance of MTB. In TDM-stimulated MH-S cells, PL significantly influenced the macrophage inducible Ca2+-dependent lectin receptor (Mincle)-Syk-ERK signalling pathway. Oral dosing of PL effectively suppressed the development of pulmonary granulomas and inflammatory reactions in the TDM-elicited mouse granuloma model.

Prevalence of Toxoplasma Gondii in Retail Fresh Meat Products from Free-range Chickens in Spain

Toxoplasma gondii is one of the most prevalent zoonotic protozoan parasites worldwide and affects the vast majority of warm-blooded animal species, including humans. Postnatal infection in humans occurs through the ingestion of sporulated T. gondii oocysts or via the oral intake of parasite tissue cysts during the consumption of raw or undercooked meat. In this regard, given their high exposure to oocysts, chickens (Gallus domesticus) raised on the ground constitute a potential source of T. gondii.
Material and methods: For the first time in Spain, a survey was undertaken in commercial retail free-range poultry. A total of 50 thighs from different animals were analysed. The samples were homogenised and an acid pepsin digestion procedure was applied prior to molecular analysis. Toxoplasma gondii DNA was isolated from meat by qPCR. Two sets of primers were used for DNA amplification targeting the specific sequence of a 529 bp repeat element and another set of primers was utilised for the surface antigen protein-1 gene.

Interrelationships between amphiregulin, kisspeptin, FSH and FSH receptor in promotion of human ovarian cell functions

The aim of this study was to investigate: (1) the ability of granulosa cells to produce amphiregulin (AREG), kisspeptin (KISS) and FSH receptor (FSHR); (2) the role of AREG and KISS in the control of ovarian functions; (3) the effect of FSH and KISS on AREG; and (4) the ability of KISS to affect FSHR and to modify FSH action on AREG output by human ovarian granulosa cells. We examined: (1) time-dependent accumulation of AREG; (2) effects of AREG (0, 1, 10, 100ng/mL) and KISS (0, 1, 10, 100ng/mL) on granulosa cell functions; and (3) the effects of KISS (0, 1, 10, 100ng/mL), FSH (0, 1, 10, 100ng/mL), and their combinations on AREG release.
Viability, markers of proliferation [accumulation ofproliferating cell nuclear antigen (PCNA) cyclin B1 and sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy6-nitro)benzene sulfonic acid hydrate (XTT formazan)] and apoptosis (accumulation of bax, caspase 3 and terminal deoxynucleotidyl transferase dUTP nick-end labelling), accumulation of KISS, FSHR and steroid hormones, and AREG release were analysed by Trypan blue exclusion test, quantitative immunocytochemistry, XTT, terminal deoxynucleotidyl transferase dUTP nick-end labelling assays and enzyme-linked immunosorbent assay.
AREG promoted cell viability, proliferation and steroid hormone output, and inhibited apoptosis. KISS (1 and 10ng/mL) stimulated viability, proliferation, steroid hormone release and occurrence of FSHR and suppressed apoptosis and AREG output; KISS (100ng/mL) had the opposite effect. FSH stimulated AREG release, whilst addition of KISS reversed this FSH effect. FSH mimicked and promoted the inhibitory effect of KISS on AREG release. These results suggest an intra-ovarian production and a functional interrelationship between AREG, KISS, FSH and FSHR in direct regulation of basic ovarian cell functions.

Novel PE and APC tandems: Additional near-infrared fluorochromes for use in spectral flow cytometry

Recent advances in flow cytometry instrumentation and fluorochrome chemistries have greatly increased fluorescent conjugated antibody combinations that can be used reliably and easily in routine experiments. The Cytek Aurora flow cytometer was first released with three excitation lasers (405, 488, and 640 nm) and incorporated the latest Avalanche Photodiode (APD) technology, demonstrating significant improvement in sensitivity for fluorescent emission signals longer than 800 nm.
However, there are limited commercially available fluorochromes capable of excitation with peak emission signals beyond 800 nm. To address this gap, we engineered six new fluorochromes: PE-750, PE-800, PE-830 for the 488 nm laser and APC-750, APC-800, APC-830 for the 640 nm laser.
Utilizing the principal of fluorescence resonance energy transfer (FRET), these novel structures were created by covalently linking a protein donor dye with an organic small molecule acceptor dye. Additionally, each of these fluorochrome conjugates were shown to be compatible with fixation/permeabilization buffer reagents, and demonstrated acceptable brightness and stability when conjugated to antigen-specific monoclonal antibodies. These six novel fluorochrome reagents can increase the numbers of fluorochromes that can be used on a spectral flow cytometer.

Paraneoplastic and Other Autoimmune Encephalitides: Antineuronal Antibodies, T Lymphocytes, and Questions of Pathogenesis

Autoimmune and paraneoplastic encephalitides represent an increasingly recognized cause of devastating human illness as well as an emerging area of neurological injury associated with immune checkpoint inhibitors. Two groups of antibodies have been detected in affected patients. Antibodies in the first group are directed against neuronal cell surface membrane proteins and are exemplified by antibodies directed against the N-methyl-D-aspartate receptor (anti-NMDAR), found in patients with autoimmune encephalitis, and antibodies directed against the leucine-rich glioma-inactivated 1 protein (anti-LGI1), associated with faciobrachial dystonic seizures and limbic encephalitis. Antibodies in this group produce non-lethal neuronal dysfunction, and their associated conditions often respond to treatment.
  • Antibodies in the second group, as exemplified by anti-Yo antibody, found in patients with rapidly progressive cerebellar syndrome, and anti-Hu antibody, associated with encephalomyelitis, react with intracellular neuronal antigens.
  • These antibodies are characteristically found in patients with underlying malignancy, and neurological impairment is the result of neuronal death. Within the last few years, major advances have been made in understanding the pathogenesis of neurological disorders associated with antibodies against neuronal cell surface antigens.
  • In contrast, the events that lead to neuronal death in conditions associated with antibodies directed against intracellular antigens, such as anti-Yo and anti-Hu, remain poorly understood, and the respective roles of antibodies and T lymphocytes in causing neuronal injury have not been defined in an animal model.
  • In this review, we discuss current knowledge of these two groups of antibodies in terms of their discovery, how they arise, the interaction of both types of antibodies with their molecular targets, and the attempts that have been made to reproduce human neuronal injury in tissue culture models and experimental animals.
  • We then discuss the emerging area of autoimmune neuronal injury associated with immune checkpoint inhibitors and the implications of current research for the treatment of affected patients.

 

COVID-19 Antigen Rapid Test Pen (Saliva)

Panbio 2

The Rapid Response COVID-19 Antigen Rapid Test Pen (Saliva) is an in vitro immunoassay. The assay is for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from saliva samples through visual interpretation of colour development. This test is intended for professional use only.

Key Benefits:

• First and the only no-spit test dedicated to COVID-19 – Its sponge-like pen tip will collect a sufficient volume of specimen in 2 mins without the need to spit and avoiding uncomfortable nasal/throat swabbing.
• ALL IN ONE – No need to waste time setting up a workstation and handle numerous assay components. All you need is one pen that can be used comfortably in any location.

Test Principle 

Anti-SARS-CoV-2 antibodies are immobilized on the test region of the nitrocellulose membrane. Anti-SARS-CoV-2 antibodies conjugated to coloured particles are immobilized on the conjugated pad. A sample is added to the extraction buffer which is optimized to release the SARS-CoV-2 antigens from specimen. During testing, target antigens, if present in the saliva samples, will be released into the extraction buffer individually packed in the kit. Consequently, the extracted antigens will bind to anti-SARS-CoV-2 antibodies conjugated to coloured particles

As the specimen migrates along the strip by capillary action and interacts with reagents on the membrane, the complex will be captured by the anti-SARS-CoV-2 antibodies at the test region. Excess coloured particles are captured at the internal control zone. The presence of a coloured band in the test region indicates a positive result for the SARS-CoV-2 viral antigens, while its absence indicates a negative result. A coloured band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking is working.

 

ï¿­ INVBIO saliva alcohol screening test kit detects alcohol presence in saliva. Therefore, directly dipping the strip into alcohol alone will not provide you with an accurate reading.
ï¿­ It is very important that the test be read at exactly two minutes, The result you read 2 minutes after saturation with saliva is the accurate test result.
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.

SPECIMEN COLLECTION AND PREPARATION
ï¿­Nothing should be placed into the mouth of the subject for at least 10 minutes prior to saliva collection. This includes food, drink, tobacco products or other materials.
ï¿­ Saliva specimen can be collected in a sputum cup or a clean container, or directly applied to the reaction pad of the test strip.

PROCEDURE:
Open the foil package and remove the test strip.
Saturate the reactive pad by dipping the reaction pad into the saliva specimen collected in a cup, or saturate the reactive pad on the end of stick with saliva in mouth for 10 seconds, shake off the excess saliva.
Immediately start timer and at exactly 2 minutes, compare the reactive pad with the provided colored chart.
Results after more than 2 minutes may be not accurate.

INTERPRETATION OF RESULTS:
­ Negative: Almost no color change by comparing with the background. The negative result indicates that the BAC is less than 0.02%.
­ Positive: A distinct color developed all over the pad. The positive result indicates that the BAC is 0.02% or higher.
­ Invalid: The test should be considered invalid If only the edge of the reactive pad turned color that might be ascribed to insufficient sampling.

 

Histopathological examination of newly-developed adhesive silicone denture relining material.

Histopathological examination of newly-developed adhesive silicone denture relining material.

We aimed to guage the subcutaneous tissue response to a newly developed adhesive silicone denture relining materials, SG, (Neo Dental Chemical Products Co., Ltd. Tokyo, Japan). We embedded the experimental materials SG and one other present management materials, Roeko Seal (RS), within the dorsal space of 22 male ddY mice.

One week and 12 weeks after the embedding, the tissues surrounding the embedded supplies had been eliminated and a histopathological examination was carried out. The outcomes reveal that the essential histopathological elements are the formation of granulation tissue and the change of the tissue to fibrous capsule over time.

The outcomes means that the newly-developed SG is secure as in contrast with the management RS, whose composition is comparable.

Histopathological examination of newly-developed adhesive silicone denture relining material.
Histopathological examination of newly-developed adhesive silicone denture relining materials.

Collaborative research on fifteen compounds within the rat-liver Comet assay built-in into 2- and 4-week repeat-dose research.

A collaborative trial was carried out to guage the likelihood of integrating the rat-liver Comet assay into repeat-dose toxicity research. Fourteen laboratories from Europe, Japan and the USA examined fifteen chemical compounds.

Two chemical compounds had been beforehand proven to induce micronuclei in an acute protocol, however had been discovered unfavorable in a 4-week Micronucleus (MN) Assay (benzo[a]pyrene and 1,2-dimethylhydrazine; Hamada et al., 2001); 4 genotoxic rat-liver carcinogens that had been unfavorable within the MN assay in bone marrow or blood (2,6-dinitrotoluene, dimethylnitrosamine, 1,2-dibromomethane, and 2-amino-3-methylimidazo[4,5-f]quinoline); three compounds used within the ongoing JaCVAM (Japanese Center for the Validation of Alternative Methods) validation research of the acute liver Comet assay (2,4-diaminotoluene, 2,6-diaminotoluene and acrylamide); three pharmaceutical-like compounds (chlordiazepoxide, pyrimethamine and gemifloxacin), and three non-genotoxic rodent liver carcinogens (methapyrilene, clofibrate and phenobarbital). Male rats obtained oral administrations of the take a look at compounds, each day for 2 or 4 weeks.

EDEM2 Antibody

6633-100 each
EUR 418.8

EDEM2 Antibody

6633-30T each
EUR 175.2

EDEM2 Antibody

46557 100ul
EUR 319

EDEM2 Antibody

46557-100ul 100ul
EUR 302.4

EDEM2 Antibody

40055-100ul 100ul
EUR 468

EDEM2 Antibody

1-CSB-PA861146LA01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

EDEM2 Antibody

E046557 100μg/100μl
EUR 255
Description: Available in various conjugation types.

EDEM2 Antibody

DF9503 200ul
EUR 420

EDEM2 Antibody

DF9503-100ul 100ul
EUR 280

EDEM2 Antibody

DF9503-200ul 200ul
EUR 350

EDEM2 Antibody

E306231 100ug/200ul
EUR 275
Description: Available in various conjugation types.

EDEM2 Antibody

E19-9503-1 50ug/50ul
EUR 145
Description: Available in various conjugation types.

EDEM2 Antibody

E19-9503-2 100ug/100ul
EUR 225
Description: Available in various conjugation types.

EDEM2 Antibody

1-CSB-PA030228
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/10000

EDEM2 Antibody

ABD9503 100ug
EUR 325

EDEM2 Antibody

MBS7120249-005mg 0.05mg
EUR 150

EDEM2 Antibody

MBS7120249-01mg 0.1mg
EUR 190

EDEM2 Antibody

MBS7120249-5x01mg 5x0.1mg
EUR 845

EDEM2 Antibody

MBS9402042-01mL 0.1mL
EUR 420

EDEM2 Antibody

MBS9402042-5x01mL 5x0.1mL
EUR 1740

EDEM2 Antibody

MBS8518514-005mg 0.05mg
EUR 235

EDEM2 Antibody

MBS8518514-01mg 0.1mg
EUR 305

EDEM2 Antibody

MBS8518514-01mLAF405M 0.1mL(AF405M)
EUR 465

EDEM2 Antibody

MBS8518514-01mLAF546 0.1mL(AF546)
EUR 465

EDEM2 Antibody

MBS8518514-01mLAF750 0.1mL(AF750)
EUR 465

EDEM2 Antibody

MBS8526978-01mg 0.1mg
EUR 345

EDEM2 Antibody

MBS8526978-01mLAF405L 0.1mL(AF405L)
EUR 565

EDEM2 Antibody

MBS8526978-01mLAF405S 0.1mL(AF405S)
EUR 565

EDEM2 Antibody

MBS8526978-01mLAF610 0.1mL(AF610)
EUR 565

EDEM2 Antibody

MBS8526978-01mLAF635 0.1mL(AF635)
EUR 565

EDEM2 Antibody

MBS1496915-005mg 0.05mg
EUR 190

EDEM2 Antibody

MBS1496915-01mg 0.1mg
EUR 270

EDEM2 Antibody

MBS1496915-5x01mg 5x0.1mg
EUR 1205

EDEM2 Antibody

MBS9609820-01mL 0.1mL
EUR 260

EDEM2 Antibody

MBS9609820-02mL 0.2mL
EUR 305

EDEM2 Antibody

MBS9609820-5x02mL 5x0.2mL
EUR 1220

EDEM2 Antibody

MBS9429704-01mL 0.1mL
EUR 305

EDEM2 Antibody

MBS9429704-5x01mL 5x0.1mL
EUR 1230

EDEM2 Antibody

C15670-100ul 100μl
EUR 217
Description: EDEM2 Rabbit Polyclonal Antibody

EDEM2 Antibody

C15670-50ul 50μl
EUR 143.5
Description: EDEM2 Rabbit Polyclonal Antibody

EDEM2 cDNA Clone

MBS1273993-001mgPlasmid02mLGlycerolStock 0.01mgPlasmid+0.2mLGlycerol-Stock
EUR 330

EDEM2 cDNA Clone

MBS1273993-5x001mgPlasmid5x02mLGlycerolStock 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock
EUR 1430

EDEM2 Rabbit pAb

MBS9142649-002mL 0.02mL
EUR 200

EDEM2 Rabbit pAb

MBS9142649-005mL 0.05mL
EUR 255

EDEM2 Rabbit pAb

MBS9142649-01mL 0.1mL
EUR 345

EDEM2 Rabbit pAb

MBS9142649-02mL 0.2mL
EUR 545

EDEM2 Rabbit pAb

MBS9142649-5x02mL 5x0.2mL
EUR 2265

EDEM2 Rabbit pAb

A17181 50μL
EUR 1246.96

EDEM2 siRNA (Human)

MBS8224905-15nmol 15nmol
EUR 405

EDEM2 siRNA (Human)

MBS8224905-30nmol 30nmol
EUR 565

EDEM2 siRNA (Human)

MBS8224905-5x30nmol 5x30nmol
EUR 2450

anti- EDEM2 antibody

FNab02632 100µg
EUR 606.3
Description: Antibody raised against EDEM2

EDEM2 cloning plasmid

CSB-CL861146HU-10ug 10ug
EUR 451.2
Description: A cloning plasmid for the EDEM2 gene.

EDEM2 Blocking Peptide

6633BP-50 each
EUR 183.6

EDEM2 Blocking Peptide

DF9503-BP 1mg
EUR 234

EDEM2 Blocking Peptide

MBS9628524-1mg 1mg
EUR 380

EDEM2 Blocking Peptide

MBS9628524-5x1mg 5x1mg
EUR 1650

EDEM2 Polyclonal Antibody

ABP55756-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

ABP55756-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of EDEM2 from Human. This EDEM2 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human EDEM2

EDEM2 Polyclonal Antibody

E917181 100ul
EUR 225
Description: Available in various conjugation types.

EDEM2 Polyclonal Antibody

E20-71458 100ug
EUR 225
Description: Available in various conjugation types.

Polyclonal EDEM2 Antibody

AMM07003G 0.1mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EDEM2 . This antibody is tested and proven to work in the following applications:

EDEM2 Conjugated Antibody

C46557 100ul
EUR 476.4

EDEM2 Polyclonal Antibody

A58890
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 µg
  • 20 ul
  • 50 ul
  • 100 ul

EDEM2 Polyclonal Antibody

E-AB-91724-120uL 120uL
EUR 320
Description: Unconjugated

EDEM2 Polyclonal Antibody

E-AB-91724-200uL 200uL
EUR 530
Description: Unconjugated

EDEM2 Polyclonal Antibody

E-AB-91724-60uL 60uL
EUR 200
Description: Unconjugated

EDEM2 Polyclonal Antibody

E-AB-91724-each each Ask for price
Description: Unconjugated

EDEM2 Polyclonal Antibody

E44H04585 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

EDEM2 Polyclonal Antibody

BT-AP02822-100ul 100ul Ask for price
Description: In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins.

EDEM2 Polyclonal Antibody

BT-AP02822-20ul 20ul Ask for price
Description: In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins.

EDEM2 Polyclonal Antibody

BT-AP02822-50ul 50ul Ask for price
Description: In the endoplasmic reticulum (ER), misfolded proteins are retrotranslocated to the cytosol and degraded by the proteasome in a process known as ER-associated degradation (ERAD). EDEM2 belongs to a family of proteins involved in ERAD of glycoproteins.

EDEM2 Polyclonal Antibody

MBS8571808-01mL 0.1mL
EUR 305

EDEM2 Polyclonal Antibody

MBS8571808-01mLAF405L 0.1mL(AF405L)
EUR 565

EDEM2 Polyclonal Antibody

MBS8571808-01mLAF405S 0.1mL(AF405S)
EUR 565

EDEM2 Polyclonal Antibody

MBS8571808-01mLAF610 0.1mL(AF610)
EUR 565

EDEM2 Polyclonal Antibody

MBS8571808-01mLAF635 0.1mL(AF635)
EUR 565

EDEM2 Polyclonal Antibody

MBS8522439-01mg 0.1mg
EUR 305

EDEM2 Polyclonal Antibody

MBS8522439-01mLAF405L 0.1mL(AF405L)
EUR 465

EDEM2 Polyclonal Antibody

MBS8522439-01mLAF405S 0.1mL(AF405S)
EUR 465

EDEM2 Polyclonal Antibody

MBS8522439-01mLAF610 0.1mL(AF610)
EUR 465

EDEM2 Polyclonal Antibody

MBS8522439-01mLAF635 0.1mL(AF635)
EUR 465

EDEM2 Polyclonal Antibody

MBS2562401-002mL 0.02mL
EUR 140

EDEM2 Polyclonal Antibody

MBS2562401-006mL 0.06mL
EUR 180

EDEM2 Polyclonal Antibody

MBS2562401-012mL 0.12mL
EUR 260

EDEM2 Polyclonal Antibody

MBS2562401-02mL 0.2mL
EUR 405

EDEM2 Polyclonal Antibody

MBS2562401-5x02mL 5x0.2mL
EUR 1725

EDEM2 Conjugated Antibody

MBS9454488-01mLAF350 0.1mL(AF350)
EUR 480

EDEM2 Conjugated Antibody

MBS9454488-01mLAF405 0.1mL(AF405)
EUR 480

EDEM2 Conjugated Antibody

MBS9454488-01mLAF488 0.1mL(AF488)
EUR 480

EDEM2 Conjugated Antibody

MBS9454488-01mLAF555 0.1mL(AF555)
EUR 480

EDEM2 Conjugated Antibody

MBS9454488-01mLBiotin 0.1mL(Biotin)
EUR 480

Human EDEM2 ELISA KIT

EF009290 96tests
EUR 566

Human EDEM2 ELISA KIT

ELI-32317h 96tests
EUR 696

Human EDEM2 shRNA Plasmid

20-abx960878
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Human EDEM2 Protein Lysate

MBS8410879-002mg 0.02mg
EUR 365

Human EDEM2 Protein Lysate

MBS8410879-5x002mg 5x0.02mg
EUR 1410

EDEM2 Antibody, HRP conjugated

1-CSB-PA861146LB01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

EDEM2 Recombinant Protein (Rat)

RP199049 100 ug Ask for price

EDEM2 Antibody, HRP conjugated

MBS1495307-005mg 0.05mg
EUR 190

EDEM2 Antibody, HRP conjugated

MBS1495307-01mg 0.1mg
EUR 270

EDEM2 Antibody, HRP conjugated

MBS1495307-5x01mg 5x0.1mg
EUR 1205

Edem2 (GFP-tagged) - Mouse ER degradation enhancer, mannosidase alpha-like 2 (Edem2)

MG209050 10 µg Ask for price

EDEM2 Antibody, FITC conjugated

1-CSB-PA861146LC01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

EDEM2 Antibody, FITC conjugated

MBS968873-005mg 0.05mg
EUR 190

EDEM2 Antibody, FITC conjugated

MBS968873-01mg 0.1mg
EUR 270

EDEM2 Antibody, FITC conjugated

MBS968873-5x01mg 5x0.1mg
EUR 1205

Edem2 (untagged) - Mouse ER degradation enhancer, mannosidase alpha-like 2 (Edem2), (10ug)

MC200261 10 µg Ask for price

OACA05949-50UG - EDEM2 Antibody

OACA05949-50UG 50ug
EUR 179

EDEM2 Recombinant Protein (Human)

RP010159 100 ug Ask for price

EDEM2 Recombinant Protein (Mouse)

RP130856 100 ug Ask for price

EDEM2 Rabbit Polyclonal Antibody

54387 100ul
EUR 439

EDEM2 Antibody, Biotin conjugated

1-CSB-PA861146LD01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against EDEM2. Recognizes EDEM2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

EDEM2 Rabbit Polyclonal Antibody

ES6755-100ul 100ul
EUR 124
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

EDEM2 Rabbit Polyclonal Antibody

ES6755-50ul 50ul
EUR 74
Description: A Rabbit Polyclonal antibody against EDEM2 from Human. This antibody is tested and validated for IHC, WB, ELISA

OACA05949-100UG - EDEM2 Antibody

OACA05949-100UG 100ug
EUR 319

EDEM2 Rabbit Polyclonal Antibody

E10G02431 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

EDEM2 Antibody, Biotin conjugated

MBS1495723-005mg 0.05mg
EUR 190

EDEM2 Antibody, Biotin conjugated

MBS1495723-01mg 0.1mg
EUR 270

EDEM2 Antibody, Biotin conjugated

MBS1495723-5x01mg 5x0.1mg
EUR 1205

EDEM2 Rabbit Polyclonal Antibody

MBS9467696-005mL 0.05mL
EUR 300

EDEM2 Rabbit Polyclonal Antibody

MBS9467696-01mL 0.1mL
EUR 390

EDEM2 Rabbit Polyclonal Antibody

MBS9467696-5x01mL 5x0.1mL
EUR 1610

Edem2 ORF Vector (Rat) (pORF)

ORF066351 1.0 ug DNA
EUR 607.2

ARP85566_P050 - EDEM2 Antibody (ARP85566_P050)

ARP85566_P050 100ul
EUR 389

Human EDEM2 Protein, His Tag

E40KMPH5204 20ug
EUR 495

Edem2 ORF Vector (Mouse) (pORF)

ORF043620 1.0 ug DNA
EUR 607.2

EDEM2 ORF Vector (Human) (pORF)

ORF003387 1.0 ug DNA
EUR 114

Edem2 (Myc-DDK-tagged) - Mouse ER degradation enhancer, mannosidase alpha-like 2 (Edem2)

MR209050 10 µg Ask for price

Human EDEM2 knockout cell line

ABC-KH4587 1 vial Ask for price
Description: Human EDEM2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Edem2 (untagged ORF) - Rat ER degradation enhancer, mannosidase alpha-like 2 (Edem2), (10 ug)

RN209981 10 µg Ask for price

Human EDEM2 knockdown cell line

ABC-KD4587 1 vial Ask for price
Description: Human EDEM2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human EDEM2 Protein Lysate 20ug

IHUEDEM2PLLY20UG each
EUR 213
Description: Human EDEM2 Protein Lysate 20ug

EDEM2 Peptide - N-terminal region

MBS3246704-01mg 0.1mg
EUR 180

EDEM2 Peptide - N-terminal region

MBS3246704-5x01mg 5x0.1mg
EUR 730

EDEM2 Peptide - N-terminal region

MBS3247363-01mg 0.1mg
EUR 180

EDEM2 Peptide - N-terminal region

MBS3247363-5x01mg 5x0.1mg
EUR 730

EDEM2 Antibody - N-terminal region

MBS3221987-01mL 0.1mL
EUR 455

EDEM2 Antibody - N-terminal region

MBS3221987-5x01mL 5x0.1mL
EUR 1995

EDEM2 Antibody - N-terminal region

MBS3222696-01mL 0.1mL
EUR 455

EDEM2 Antibody - N-terminal region

MBS3222696-5x01mL 5x0.1mL
EUR 1995

EDEM2 (untagged)-Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 2

SC326050 10 µg Ask for price

EDEM2 (untagged)-Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 1

SC320190 10 µg Ask for price

OCOA19334-20UG - EDEM2 Protein Lysate

OCOA19334-20UG 20ug
EUR 169

OCOA02410-20UG - EDEM2 Protein Lysate

OCOA02410-20UG 20ug
EUR 169

EDEM2 Over-expression Lysate Product

GWB-CACD60 0.1 mg Ask for price

EDEM2 Polyclonal Antibody, HRP Conjugated

A58893
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 µg
  • 50 ul
  • 100 ul

Human EDEM2 HEK293 Overexpression Lysate

MBS8115551-03mg 0.3mg
EUR 280

Human EDEM2 HEK293 Overexpression Lysate

MBS8115551-5x03mg 5x0.3mg
EUR 1205

EDEM2 Polyclonal Antibody, FITC Conjugated

A58892
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 µg
  • 50 ul
  • 100 ul

EDEM2 Polyclonal Antibody, Biotin Conjugated

A58891
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 µg
  • 50 ul
  • 100 ul

Edem2 (Myc-DDK-tagged ORF) - Rat ER degradation enhancer, mannosidase alpha-like 2 (Edem2), (10 ug)

RR209981 10 µg Ask for price

C20orf31 (EDEM2) (NM_018217) Human Over-expression Lysate

LS055741 100ug
EUR 628
Description: Transient overexpression lysate of ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 1

EDEM2 (GFP-tagged) - Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 2

RG227309 10 µg Ask for price

EDEM2 (GFP-tagged) - Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 1

RG200124 10 µg Ask for price

Lenti ORF clone of Edem2 (mGFP-tagged) - Mouse ER degradation enhancer, mannosidase alpha-like 2 (Edem2)

MR209050L4 10 µg Ask for price

Edem2 sgRNA CRISPR Lentivector set (Rat)

K7428201 3 x 1.0 ug
EUR 406.8

EDEM2 Protein, Human, Recombinant (His Tag)

MBS8121941-01mg 0.1mg
EUR 450

EDEM2 Protein, Human, Recombinant (His Tag)

MBS8121941-5x01mg 5x0.1mg
EUR 1885

Edem2 sgRNA CRISPR Lentivector set (Mouse)

K3235601 3 x 1.0 ug
EUR 406.8

EDEM2 sgRNA CRISPR Lentivector set (Human)

K0653501 3 x 1.0 ug
EUR 406.8

EDEM2 3'UTR GFP Stable Cell Line

TU056560 1.0 ml
EUR 1672.8

Edem2 3'UTR GFP Stable Cell Line

TU253777 1.0 ml Ask for price

Edem2 3'UTR GFP Stable Cell Line

TU155598 1.0 ml Ask for price

EDEM2 (Myc-DDK-tagged)-Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 1

RC200124 10 µg Ask for price

EDEM2 (Myc-DDK-tagged)-Human ER degradation enhancer, mannosidase alpha-like 2 (EDEM2), transcript variant 2

RC227309 10 µg Ask for price

Lenti ORF clone of Edem2 (Myc-DDK-tagged) - Mouse ER degradation enhancer, mannosidase alpha-like 2 (Edem2)

MR209050L3 10 µg Ask for price

EDEM2 Protein Vector (Rat) (pPM-C-HA)

PV265404 500 ng
EUR 723.6

The prime dose was meant to be the very best dose producing scientific indicators or histopathological results with out inflicting mortality, i.e. the 28-day most tolerated dose. The liver Comet assay was carried out in accordance with revealed suggestions and following the protocol for the continuing JaCVAM validation trial. Laboratories supplied liver Comet assay knowledge obtained on the finish of the long-term (2- or 4-week) research along with an analysis of liver histology.

Most of the take a look at compounds had been additionally investigated within the liver Comet assay after short-term (1-Three each day) administration to match the sensitivity of the 2 research designs. MN analyses had been carried out in bone marrow or peripheral blood for many of the compounds to find out whether or not the liver Comet assay might complement the MN assay for the detection of genotoxins after long-term therapy.

Most of the liver genotoxins had been optimistic and the three non-genotoxic carcinogens gave unfavorable end result within the liver Comet assay after long-term administration. There was a excessive concordance between short- and long-term Comet assay outcomes. Most compounds when examined as much as the utmost tolerated dose had been accurately detected in each short- and long-term research.

Discrepant outcomes had been obtained with 2,6 diaminotoluene (unfavorable within the short-term, however optimistic within the long-term research), phenobarbital (optimistic within the short-term, however unfavorable within the long-term research) and gemifloxacin (optimistic within the short-term, however unfavorable within the long-term research).

The total outcomes point out that the liver Comet assay will be built-in inside repeat-dose toxicity research and effectively enhances the MN assay in detecting genotoxins. Practical elements of integrating genotoxicity endpoints into repeat-dose research had been evaluated, e.g. by investigating the impact of blood sampling, as usually carried out throughout toxicity research, on the Comet and MN assays.

The bleeding protocols used right here didn’t have an effect on the conclusions of the Comet assay or of the MN assays in blood and bone marrow. Although bleeding typically elevated reticulocyte frequencies, the sensitivity of the response within the MN assay was not altered.